In line with this, patients with CS‐ACC were recently reported to experience decreased response to immunotherapy and experience poor patient outcomes compared to nonCS‐ACC patients when treated with anti‐PD‐L1 agent Pembrolizumab and mitotane.25 Here, CD274 is linked to adrenal cortex carcinoma.